Farmas USA

GILD
Probablemente por el momento se dedique a hacer buyback de su propio stock

PFE

-2% dropping its cholesterol drug trials.

Chinese regulators have approved Pfizer's (NYSE:PFE) blockbuster vaccine Prevenar 13, a breakthrough for the firm after it was forced to shut its vaccine business in the country last year. As one of Pfizer's top selling products, Prevenar is used primarily for infants to help prevent pneumococcal disease, a bacterial infection that can lead to illnesses such as pneumonia, meningitis and sepsis.

GILD

Esto es lo que dijo ayer el CEO sobre adquisiciones, que en lo que están interesados estaba o muy verde o era muy caro...

While the company remains "open minded" and "very active" on the M&A front, Milligan conceded that some of the assets they look at were too early, while others were too expensive. Gilead won't stray from its "disciplined" M&A standards just because everyone outside the company is urging them to get a deal, or a series of deals, done, said Milligan.

GILD
Mas vale que espabilen. Ya perdieron el bid de TBRA por quedarse cortos. Si es caro es por algo. Me suena excusa eso de caro o muy verde. Tengo que decir que me esperaba más del nuevo management de GILD

Prevenar en China .... buf $$$$

VCYT

Colocación a 6$. Voy a mirarla un poco. Puede dar opción de corto probablemente en pre. Si alguien sabe algo de ella que grite rápido.

underwritten public offering
of 5,000,000 shares of its common stock at a public offering price of $6.00
per share. The gross proceeds to Veracyte from this offering, before deducting
underwriting discounts and commissions and offering expenses payable by
Veracyte, are expected to be $30 million. All of the shares are being
offered by Veracyte. The offering is scheduled to close on or about November
7, 2016, subject to customary closing conditions. In addition, Veracyte has
granted to the underwriters participating in the offering a 30-day option to
purchase up to an additional 750,000 shares of its common stock at the public
offering price, less underwriting discounts and commissions.

PTN

Por el Bastardo:

Palatin Female Libido-Boosting Shot Fails Crucial Sex Frequency Test

https://www.thestreet.com/story/13876716/1/palatin-female-libido-boosting-shot-fails-crucial-sex-frequency-test.html

CEMP

Pinta mal. De Twitter:

Long list of safety/pharmacokinetic/efficacy issues that FDA identified

As expected, liver tox is the key focus of solithromycin safety issues

more than 40 cases of severe telithromycin-related hepatotoxicity resulting in 4 deaths and a liver transplantation"

Edito, del documento:

Summary
A significant safety signal for hepatotoxicity
was observed in the sol
ithromycin development
program. The rates of transaminase elevations
were higher in solithromycin- treated patients
than those treated with moxifl
oxacin and were related to solithromycin exposure. The high
rate of infusion site-related r
eactions associated with solith
romycin (31.3%) as compared to
moxifloxacin (5.2%) is a
nother safety concern.

In the solithromycin development program
to date, a range of patterns of liver
injury associated with exposure to solithromy
cin were observed. There was a spectrum of
both hepatocellular and cholestatic signatures
of hepatotoxicity, in one case accompanied by
eosinophilia and suggesting hypersensitivity as a
mechanism for liver injury. These findings
were noted among a relatively small number of
patients treated with so
lithromycin for CABP
(n=920), normal healthy volunteers exposed to th
e drug in PK studies, and a small number of
patients administered solithromycin in studies of
other conditions. We conclude that these
findings comprise a genuin
e liver injury signal.
Despite the differences in chemical structur
e, the hepatic advers
e effects seen with
solithromycin during its development program ex
ceed the pre-marketing hepatic signal seen
with telithromycin. Significant gaps in knowle
dge of the hepatic t
oxicity profile of
solithromycin exist. For example, the likelihood
of serious idiosyncratic liver injury in a
larger population and the impact of prior sensit
ization to macrolides on solithromycin-induced
liver injury are unknown.
The difference in peak ALT values between the
treatment groups in CABP trials should be
considered in the context of the established
moxifloxacin safety prof
ile. The WARNINGS
AND PRECAUTIONS Section in the moxifloxacin
product labeling describes “Other Serious
and Sometimes Fatal Adverse Reactions” that
include “hepatitis; jaundice; acute hepatic
necrosis or failure”.